Despite unprecedented events in public health and politics, the US Food and Drug Administration’s 2021 story about novel agent approvals hit some familiar (but nonetheless impressive) notes: another year of novel drug approval counts that would have been unfathomable in the first decade of the 2000s.
The FDA’s drug and biologics centers approved a combined total of 60 novel agents, just the second time the combined...






